(Q37283006)

19 August 2017

1 reference

title

Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome (English)

1 reference

19 August 2017

R Forastiero

1

1 reference

19 August 2017

M Martinuzzo

series ordinal

2

1 reference

19 August 2017

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

17

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

872-877

1 reference

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Current concepts on the pathogenesis of the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Antiphospholipid antibodies: lessons from the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Fibrinolytic balance and lupus anticoagulant in patients with repeated spontaneous fetal loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308091633

21 January 2018

Identifiers

DOI

10.1177/0961203308091633

1 reference

19 August 2017

1 reference